Healthesystems is attending the Ohio Bureau of Workers’ Compensation Safety Congress & Expo, the nation’s largest free occupational safety conference focusing on helping employers improve safety and health within their business.
Healthesystems is attending the IRSG Conference, which is designed for leaders in the insurance, medical, and rehabilitation fields.
Approval Date: Jul 2024
Indicated for the treatment of hypertension alone or with other antihypertensive agents, and for the treatment of enlarged prostate
Approval Date: Jul 2024
Indicated for the treatment of mild to moderate dementia of the Alzheimer's type
Approval Date: Jul 2024
Indicated for the treatment of moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more TNF blockers
Approval Date: Jul 2024
Indicated for the treatment of Alzheimer's disease. Treatment with Kisunla should be initiated in patient with mild cognitive impairment or mild dementia stage of disease, the population in which the treatment was initiated in the clinical trials
Approval Date: Jun 2024
Indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management
Approval Date: Jun 2024
Indicated for the treatment of erectile dysfunction
Approval Date: Jun 2024
A biosimilar to Stelara; indicated for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, moderately to severely active Crohn’s disease, and moderately to severely active ulcerative colitis
Approval Date: Jun 2024
A new chewable tablet indicated for the treatment of erectile dysfunction, and the signs and symptoms of benign prostatic hyperplasia
Approval Date: May 2024
Indicated for the treatment of HIV-1 infection, in combination with other antiretroviral agents
Approval Date: May 2024
Indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure
Approval Date: Apr 2024
Indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression
Approval Date: Apr 2024
A biosimilar of Stelara®, this drug is indicated for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis
Approval Date: Mar 2024
A long-acting, atypical antipsychotic indicated for the treatment of schizophrenia
Approval Date: Mar 2024
A first-in-class biologic indicated for the treatment of pulmonary arterial hypertension to increase exercise capacity and reduce the risk of clinical worsening events
Approval Date: Mar 2024
Indicated for the treatment of pulmonary arterial hypertension, both in patients who are treatment naïve or who are already on an ERA, PDE5 inhibitor or both
